Clinical trial · Observational
MammaPrint Value for Pre-menopausal Breast Cancer Patients
The Value of MammaPrint in Adjuvant Therapy Decision Among Pre-menopausal Breast Cancer Patients: a Survey Based on Clinical Staff
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Nearly 200 cases are to be enrolled. The information of patient age, histologic grade, tumor size, ER and PR status, Ki-67 index, surgery mode should be provided. The adjuvant therapy regime (chemotherapy: none, TC\*4, TC\*6 or EC-T; endocrine therapy: TAM, OFS+TAM, OFS+AI) will be compared before and after MammaPrint testing. About 20 clinical staffs are enrolled to participate in this survey for the clinical decision making. Each case could be chosen five times at random.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- MammaPrint group
- description
- Pre-menopausal breast cancer patients received MammaPrint test.
Primary outcomes (1)
- measure
- Treatment decision survey
- timeFrame
- 6 weeks
- description
- Treatment decision change after MammaPrint testing
Eligibility
Eligibility (as posted)
- Sex
- Female
- Maximum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: 1. pre-menopausal breast cancer patients aged less than 50 years old. 2. Pathology confirmed invasive dutal carcinoma or invasive lobular carcinoma. 3. receiving breast conserving surgery or mastectomy with/without reconstruction; sentinel lymph node biopsy or axillary lymph node dissection. 4. TNM staging: T1b-T2N0-1M0. 5. molecular subtype: ER positive/HER2 negative. 6. MammaPrint testing before initiation of adjuvant therapy. Exclusion Criteria: 1. Incomplete medical history. 2. Pregnancy or lactation. 3. Contradiction of chemotherapy or ovarian function suppression.
References
Publications (0)
Data not yet available